Objective To assess the effectiveness and safety of Shenfutuodu capsule in the treatment of opioid withdrawal syndrome. Methods We searched The Cochrane Library （Issue 1 , 2005 ） , MEDLINE （1966 -2005） , EMBASE （1974-2005） , and some Chinese databases for additional articles （CBMdisc, CMCC, VIP, CNKI ） （1980-2005 ）. The quality of included randomized controlled trials was evaluated and meta-analysis was performed.Results Our initial search identified just three studies involving 293 patients met the inclusion criteria and were of higher quality. There was a statistical difference between Shenfutuodu capsule and clonidine groups on the fifth day in withdrawl symptom score with weight mean difference （WMD） -3.14 and 95% confidence interval （CI） -6.28 to -0.01. And no statistical difference was detected between the two groups in withdrawal symptom score on the 0th-4th day and the 6th-10th daywith WMD 58.45（95% CI 53.88 to 63.02）, -1. 15 （95% CI -5.69 to 3.40） , -0.42（95% CI -4.55 to 3.70）, -0.77（95%CI -4.37 to 2. 84）, -1.54（95%CI -4.78 to 1.69）, -1.76（95%CI -4.25 to0.74） , -1.74（95%CI -3.89 to0.41）, -1.24（95%CI -3.28 to0.80）, -0.52（95%CI -1.96 to0.92 ） and -0.27（95% CI -1.64 to 1.11 ） respectively. There was no statistical difference on effectiveness between the two groups on the third day with WMD 1.52, （95% CI 0.79 to 2.95）. There was no statistical difference between the two groups in HAMA score on the first , fifth and tenth day with WMD -0.55（95% CI -3.74 to 2.64） , 0.34 （95% CI -2.02 to 2.70） , 0. 63 （95% CI -0.21 to 1.47 ） respectively. There was a statistical difference between the two groups in dizziness rate with RR 0.73 （95% CI 0.62 to 0.87 ） . No statistical difference was detected between the two groups in dry mouth with RR 1.11（95% CI 0.95 to 1.29） , somnolence with RR 0.99（95% CI 0.82 to 1.21） , and blurred vision with RR 0.92（95% CI 0.70 to 1.19）. Statistical difference was detected between the two groups in side effect score on the second day with WMD -1.26 （95% CI -2.40 to -0. 12 ）. No statistical difference was detected between the two groups in side effect score on the first day, the third to tenth day with WMD -0.55 （ 95% CI -1.48 to0.38）, -0.63 （95%CI -1.67 to0.42）, -0.84 （95%CI -1.77 to0.09）, -0.29 （95%CI -1.09 to 0.51）, 0.15 （95% CI -0.52 to 0.81）, 0. 22 （95% CI -0.22 to 0.67）, 0.09（95% CI -0.25 to 0.44）, 0.03 （95% CI -0.21 to 0.27） , -0.03 （95% CI -0.33 to 0.26） respectively. Conclusions Based on the current evidence, Shenfutuodu capsule may be an effective and safe drug or abstinence of drug addiction. More well designed randomized controlled trials are required .
目的 探讨联合康复新液治疗复治菌阳肺结核的临床效果。 方法 选取2011年1月－12月复治菌阳肺结核患者120例，随机分为对照组57例，观察组63例。两组患者均采取异烟肼、利福平、吡嗪酰胺、乙胺丁醇、链霉素联合治疗；观察组在此基础上再联用康复新液予以辅助治疗。治疗期间随访患者临床症状、痰菌阴转、病灶吸收情况，并就两组患者治疗效果进行评价。 结果 治疗2、3、6、8个月时观察组患者痰菌转阴率分别为46.03%、73.02%、90.48%和95.23%，明显高于对照组（26.32%、49.12%、66.66%、84.21%）；治疗6个月后胸部CT检查示观察组患者空洞闭合率为73.58%；对照组患者空洞闭合率为52.08%，两组比较差异有统计学意义（χ2=5.016，P=0.025）；治疗过程中的不良反应发生率观察组为19.04%，对照组为19.30%，两组比较差异无统计学意义（χ2=0.001，P=0.972）。 结论 对复治菌阳肺结核联合康复新液进行治疗是一种安全而有效的治疗方法。